Article
Vaccination with CD47 deficient tumor cells elicits an antitumor immune response in mice.
Nature communications - 29 Jan 2020
Li Yang, Zhang Mingyou, Wang Xiaodan, Liu Wentao, Wang Hui, Yang Yong-Guang
Abstract excerpt
Cancer cells are poorly immunogenic and have a wide range of mutations, which makes them unsuitable for use in vaccination treatment. Here, we show that elimination of CD47, a ligand for the myeloid cell inhibitory receptor SIRPα, from tumor cells by genetic deletion or antibody blocking, significantly improves the effectiveness of the immune response to tumour cells. In both solid and hematopoietic mouse tumor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.